Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from a Clinical Experience Program for its first-in-class, proprietary blood test for Major Depressive Disorder (MDD) will be presented during a poster session entitled Clinician Acceptance and Utility of a Multianalyte Biomarker Panel for Major Depressive Disorder (MDD) Diagnosis.
The blood test, for the first time, provides clinicians with biological information derived from physiological changes associated with MDD. By adding an objective, biological basis, the blood test results are intended to augment the paradigm used for neuropsychiatric diagnosis and patient management.
"We are pleased to once again report significant findings from our clinical studies, and those of our collaborators, to the psychiatric community at the U.S. Psychiatric and Mental Health Congress," stated Lonna J. Williams, CEO of Ridge Diagnostics. "Physicians who participated in our Clinical Experience Program found the MDDScore results provide an objective insight to a patient's diagnosis and management while at the same time provides the patients and their families with a clearer understanding of their condition."
The poster will be presented by Dr. John Bilello, Chief Scientific Officer of Ridge.
Spear Bio secures FDA breakthrough device designation for its novel pTau 217 blood test, advancing scalable solutions for early Alzheimer's disease diagnosis